| Developers: | Moderna |
| Date of the premiere of the system: | August 2020 |
| Branches: | Pharmaceuticals, Medicine, Healthcare |
2024: COVID vaccine-vaccinated Pfizer and Moderna massively develop neurological and cardiovascular diseases
Vaccines against coronavirus, COVID-19 including drugs, and Pfizer, BioNTech Moderna can provoke the development of neurological and cardiovascular diseases. This is stated in a large-scale study by the Global Vaccine Data Network (GVDN), the results of which were published on February 19, 2024. More. here
2023: Moderna and Pfizer hide deadly danger of their mRNA vaccines
Disclosed confidential documents indicate that Pfizer had data indicating the deadly danger of the mRNA vaccine against COVID-19. However, the pharmaceutical company chose to hide this information, as reported on March 16, 2023 by members of the American activist group Project Veritas. Read more here.
2021
First direct comparison of mRNA vaccines shows Moderna's superiority over Pfizer
In early December 2021, it became known that a comparison of mRNA vaccines showed the superiority of Moderna over Pfizer, it was previously reported that vaccines protect vaccine recipients from 94-95% of symptomatic and severe forms of coronavirus (COVID-19) infection. Real-time surveillance has shown that their effectiveness decreases over time, allowing re-infection or breakthrough infection to occur even in fully vaccinated individuals.
This situation has worsened with the introduction of the Delta variant, which prompts the introduction of booster doses six or more months after initial vaccination. A recent preprint looks at the effectiveness of this strategy based on data from the Veterans Health Administration (VHA) to compare the protection against the infection the vaccine provided with the protection given by the primary two-dose regimen. The current study, the results of which are posted on the open-label medical project medRxiv, used electronic medical records to assess the effectiveness of the booster dose in the United States against post-vaccination COVID-19. Treatment and control cohorts were matched by age, sex and other demographic parameters, by positive virus tests and underlying medical conditions, and by the completion date of the primary vaccination series.
The study included almost 440 thousand fully vaccinated people, with almost equal shares of Pfizer and Moderna vaccines. About 36% and 27% then received a third dose of either vaccine, respectively. There were 74 thousand and 55 thousand matching pairs of recipients of primary and booster doses of Pfizer and Moderna vaccines. The median age in both groups was 72 years, with 94% in both groups being male. Less than 2% in both groups were ever positive for the virus, but most were not tested for 90 days before the study began. Over 16 days of follow-up in the BNT162b2 group, the incidence of COVID-19 infection was 0.8% and 0.4% among recipients of the primary series and third dose, respectively, and hospitalization occurred in 0.2% and 0.1% of cases in these two groups. In the other group, infection rates were 0.6% and 0.3%, and hospitalization occurred in 0.2% versus 0.1% in both subgroups.
This means that third-dose boosters BNT162b2 and mRNA-1273 prevented nearly half of post-vaccination infections and hospitalizations, respectively, in this cohort, regardless of age. However, in healthier people, the degree of protection was slightly higher. Overall, the risk of hospitalization was not significantly altered by the third dose of booster in the current analysis of elderly patients. With extension of follow-up to 90 days, the incidence of infections and hospitalization in the primary BNT162b2 series group was 2% and 0.5%. However, after the third dose of booster vaccination, the frequency of infections decreased by almost 50%.
This study used data from the largest healthcare system in the U.S. to compare the effectiveness of a third dose of vaccines in real time versus the primary series. With the use of the third dose of vaccine, the BNT162b2 risk of infection and hospitalization decreased by 45%, and with the use of the third dose of Moderna mRNA-1273 by 47% and 50%. The results suggest a moderate reduction in post-vaccination infections in individuals who received a third dose of the vaccine 6 months after completion of the primary series of BNT162b2 or mRNA-1273; improvement with respect to documented SARS-CoV-2 infection and COVID-19 hospitalization occurs within 5 and 10 days after the third dose.
The results of this study do not reflect the high efficacy observed in Israel when using the third dose of the booster from Pfizer, perhaps because the incidence of COVID-19 in these two countries was completely different during the study periods. In addition, adherence to non-drug measures aimed at preventing the transmission of COVID-19 in the two countries was completely different, which could lead the Israeli study to higher efficacy rates. This study is more generalizing as it presents individuals at higher risk of infection at baseline. It shows a moderate reduction in the risk of mild to severe infections after vaccination with a third dose of either vaccine, which is likely due to increased levels of neutralizing antibodies. It has also been found that the Delta variant spreads with equal ease from fully vaccinated individuals to their contacts. Further suppression of spread may occur with wider vaccination coverage, resulting in a reduced contingent of susceptible individuals in the population.[1]
Hungary: Sputnik V better protects against death from coronavirus than Pfizer, Moderna and AstraZeneca vaccines
At the end of November 2021, the Russian Direct Investment Fund (RDIF) published the results of an independent study of vaccines against the coronavirus COVID-19 in Hungary. According to the results of this work carried out by the National Center for Public Health of Hungary ( NPHC), Sputnik V shows higher protection against deaths (98%) compared to other drugs that are used in the country to vaccinate the population. The study was conducted on the basis of an analysis of vaccination data by two components of the Sputnik V vaccines, Moderna, Pfizer-BioNTech, Sinopharm and AstraZeneca of Hungarian residents from January 22 to June 10, 2021. Read more here.
Comparison of morbidity and mortality rates with other vaccines
At the end of October 2021, representatives of the authorities health care USA for the first time disclosed information about vaccines received by residents Oregon State who, after vaccination, had cases of disease, COVID-19 hospitalization and death.
The highest mortality rate from COVID-19 among vaccinated patients was detected using the Johnson & Johnson vaccine. It amounted to 3.14 cases per 100 thousand people. In second place in terms of mortality are patients who received the Pfizer vaccine (1.43 per 100 thousand). The lowest mortality was observed during vaccination with Moderna. Read more here.
Sweden and Denmark stop vaccination of young people with Moderna drug due to high risk of heart inflammation
Sweden and Denmark have decided to suspend vaccination of young people with Moderna Inc. Covid-19 due to possible side effects.
On October 6, 2021, the Swedish health authority cited new data on the increased risk of heart inflammation as the reason for the suspension of vaccination of persons under the age of 30. Denmark will stop giving the jab to those under the age of 18.
Increased risk of myocarditis and pericarditis
In August 2021, the US FDA reported that post-marketing data from Moderna vaccine demonstrate an increased risk of myocarditis, pericarditis, especially within 7 days after the 2nd dose.
Withdrawal of 1.6 million doses of vaccine from sale in Japan due to marriage
In August 2021, Japan seized 1.63 million doses of Moderna vaccine produced in Spain after detecting "foreign substances" in vials
health care Japan The ministry ordered Takeda Pharmaceutical Company Limited, which is responsible for distributing the Moderna vaccine in this country, to withdraw from circulation 1.63 million doses of this vaccine, in the vials of which "foreign substances" were found, according to the digital publication Kyodo News
After identifying the batches containing these "foreign substances," the Japanese Ministry of Health stated that these batches numbered: 3004667, 3004734 and 3004956 were produced on a production line that Moderna has in Spain. "
Increase in vaccine price for the EU $22.6 to $25.5
At the end of July 2021, Pfizer and Moderna raised the cost of their coronavirus vaccines for EC [2]]. The cost of Pfizer has risen from €15.5 to €19.5, and the price of the Moderna vaccine dose has risen from $22.6 to $25.5.
The terms of the deals were revised after data from phase three trials showed Pfizer and Moderna's mRNA-based vaccines were more effective than cheaper vaccines developed by AstraZeneca and Johnson & Johnson.
In 2021, these groups will receive tens of billions dollars of income, they have entered into new deals with countries seeking to provide supplies for re-vaccination.
European regulator confirms onset of heart disease after Moderna inoculation
In mid-July 2021, the European regulator EMA concluded that after the introduction of mRNA vaccines Comirnaty (manufactured by Pfizer) and Spikevax (formerly the COVID-19 Moderna vaccine) in very rare cases, the development of myocarditis and pericarditis is possible. Read more here.
The European Commission signed an additional contract with Moderna for the supply of 150 million doses of vaccine
In June 2021, the European Commission signed an additional contract with Moderna for the supply of 150 million doses of vaccine.
EC representative Stefan De Keersmaker explained at a briefing in Brussels that we are talking about an "addition to the contract with Moderna," according to which "the vaccine can be delivered from the third quarter of 2021 to 2022."
Hundreds of cases of inflammation of the heart muscle recorded after vaccination with Moderna
In mid-June 2021, the authorities health care USA confirmed the development of 226 cases of myocarditis or pericarditis in people aged 30 years and younger who received Pfizer/BioNTech vaccine Moderna it for prevention. COVID-19 About 250 more messages are under consideration. More. here
Side effects of Moderna vaccine captured on X-rays
In early May 2021, a message was published in the journal Radiology about some radiological features of the immune response to vaccines Pfizer Moderna and against administration. COVID-19 The authors of the article "Lymphadenopathy associated with vaccination with COVID-19: What to know" note that doctors and patients need to be aware of the possible development of lymphadenopathy caused by vaccination, and not confuse it with more serious conditions. More. here
WHO approves vaccine for emergency use
In April 2021, WHO included the Moderna coronavirus vaccine in the list of recommended for use in emergency situations, making this vaccine the fifth approved by WHO.
The drug is based on m-RNA and, according to WHO estimates, has an efficacy of 94.1%.
After the introduction of the vaccine, Moderna dies more often than from Sputnik V
In April 2021 Russian Direct Investment Fund (RDIF) , he published the results of a study of mortality after the introduction of coronavirus vaccines COVID-19 different manufacturers. To compile the report, publicly available data from 13 medical regulators USA France Germany Great Britain(,,,,,,,,,,,,, and) were studied. Norway Austria Italy India Argentina Brazil Chile It turned out Denmark Russia that after the introduction of the vaccine, they die more often Moderna than from "." More.Sputnik V here
Birth of children with antibodies to coronavirus
In mid-March 2021, researchers reported that a girl born three weeks after the mother was given the Moderna vaccine against COVID-19 was found to have antibodies to this virus. These antibodies have penetrated the placenta and could protect the baby during the first months of life, according to researchers at Florida Atlantic University. Read more here.
Detection of delayed side effects
In early March 2021, researchers reported immediate and delayed side effects of Moderna's SARS-CoV-2 vaccine found in phase 3 clinical trials. From analysis of skin biopsies, the researchers confirmed that the cause was delayed-type hypersensitivity.
Immediate injection site reactions were observed in 84.2% of participants after the first dose, delayed injection site reactions (defined in this study as reactions starting on or after Day 8) were observed in 244 of 30,420 participants (0.8%) after the first dose, and in 68 participants (0.2%) after the second dose. These reactions included redness, induration and tenderness and usually took place over the next 4-5 days.
In addition, the researchers observed delayed large local reactions starting on days 4-11 after the first dose. These reactions had different appearance, including grade 3 plaques (≥10 cm in diameter). Some patients experienced concomitant systemic side effects and additional skin symptoms. Most patients received treatments such as antihistamines or glucocorticoids. Symptoms disappeared on average 6 days after onset (2 to 11 days).
Given that neither local injection site reactions nor delayed-type hypersensitivity reactions are contraindications to subsequent vaccination, all 12 patients with large local reactions were recommended to receive a second dose and completed the vaccination course. At the same time, three patients again had local reactions that were similar to the response to the initial administration of the vaccine, and three more patients developed a recurrence of a lower severity than after the initial dose. On average, skin symptoms after the second dose, appearing on day 1-3, developed earlier than after the first dose.[3]
Death of coronavirus-vaccinated patients in Switzerland
At the end of February 2021, it became known about the death in Switzerland of 16 people who were previously vaccinated with vaccines against the coronavirus COVID-19, developed by Pfizer and Moderna. Read more here.
Death of dozens of patients after vaccine in US
On January 16, 2021, it became known about the death in the United States of 55 people after vaccination with vaccines against the coronavirus COVID-19, which were developed by Pfizer and Moderna.
According to The Epoch Time, citing reports from medical institutions and comments from relatives, patients died within a few days after receiving vaccinations. So, a 66-year-old resident of a nursing home in Colorado felt drowsy after vaccination and did not get out of bed all day. The next morning he was found dead in bed with his eyes half open and foaming at the mouth.
In some cases, death occurred in those vaccinated a few hours after vaccination. In South Dakota, a 93-year-old man vaccinated with Pfizer/BioNTech on January 4 at about 11 in the morning began to feel unwell two hours later. He admitted that he was tired and could not continue the course of physiotherapy. Then his legs "became heavier" and he stopped breathing.
It is noted that in addition to deaths, Americans reported 96 life-threatening complications after vaccination, as well as 24 cases of disability. The database also states that 225 patients required hospitalization after injecting a vaccine against coronavirus, and more than 1.3 thousand people went to emergency rooms on their own.
Nancy Messonnier, head of the US National Center for Immunization and Respiratory Diseases, said severe allergic reactions to COVID-19 vaccines occurred at a rate of 11 per million vaccinations compared to 1.3 per million after flu shots.
The US Food and Drug Administration (FDA) said that any reports of death after the introduction of vaccines are immediately and thoroughly investigated by the department in conjunction with the country's Ministry of Health.[4]
2020
Destruction of 400 thousand doses of vaccine due to production problems
At the end of December 2020, Moderna destroyed 400 thousand doses of its COVID-19 coronavirus vaccine due to production problems. Monsef Slaui, adviser to the US presidential administration on vaccines, told reporters about this.
According to him, at the final stage of the production of the drug, problems arose during filtration, as a result of which these doses did not have time to be placed in ampoules.
400 thousand doses were part of a wider batch of the drug of 1.4 million, intended for vaccination of US citizens. Sloughi noted that such problems are inevitable and always happen with such a difficult mass production of drugs. He added that these problems at Moderna will not affect the total volume or pace of production, and vaccine manufacturers are very closely monitoring its production.
Moderna will still be able to produce the planned 20 million doses of the vaccine in December 2020 and 85 to 100 million doses for the United States in the first quarter of 2021, according to company spokesman Ray Jordan. The cost of the dose will be from $25 to $37.
Moderna previously applied to the U.S. Food and Drug Administration (FDA) for emergency use of its vaccine. Moderna claims that its coronavirus vaccine was effective in 94.1% of cases in the primary analysis , and 100% in severe cases. The European Commission has authorized the Moderna vaccine.
Moderna's COVID-19 vaccine is administered as two injections into the arm 28 days apart. The most common side effects from Moderna's COVID-19 vaccine are described as mild to moderate and disappear within days of vaccination. The most common such effects were pain and swelling at the injection site, fatigue, chills, fever, enlargement or tenderness of the lymph nodes under the arm, headache, muscle and joint pain, nausea and vomiting.[5]
Pharmacist in the United States destroyed hundreds of doses of vaccines against coronavirus Moderna, considering them harmful to DNA
As it became known in early January 2021, the pharmacist American 44-year-old pharmacist Stephen Brandenburg destroyed hundreds of doses of vaccines from Coronavirus COVID-19, considering them harmful to human health - according to the pharmacist, injections force human DNA mutate and turn people into monsters. Read more here.
Sixth place in the ranking of the most popular vaccines against COVID-19
At the end of November 2020, Bloomberg published a rating of the most popular vaccines against the coronavirus COVID-19 according to the calculations of the London research firm Airfinity. Sputnik V is in 7th place, and the AstraZeneca vaccine tops the list, which most of the world counts on, with the exception of very rich countries like the United States. Read more here.
Record price $37 per dose
In November 2020, it became known that the Moderna COVID-19 vaccine will mainly enter the American market in the first stages.
Federal funding was allocated for the development of this vaccine by the US administration. "By the end of the year, the company aims to bring 20 million doses of the vaccine to the American market."
It is important to note that the vaccine is very expensive. In the summer, Moderna announced a price of $37 per dose, which is more expensive than Pfizer ($20) and Johnson & Johnson ($10). Perhaps if you buy large batches, Moderna will be ready to cut the price.
"However, either way it is a for-profit company and it has clearly explained that it aims to generate revenue."
Given the ties with the American administration and the high price, the rest of the world will be forced to wait, or buy alternative vaccines.
US authorities ordered 100 million doses of COVID-19 vaccine from Moderna for $1.5 billion
In August 2020, the US authorities ordered 100 million doses of COVID-19 vaccine from Moderna in the amount of $1.5 billion. Deliveries will begin after the drug, called mRNA-1273, is registered and fully ready for mass use.
Two doses of the mRNA-1273 vaccine required for vaccination will thereby cost $30.5. At the end of July, Moderna announced the start of the most massive clinical trial of such a vaccine. The US authorities have invested a total of $950 billion in these developments of the pharmaceutical company. Moderna plans to release at least 500 million doses of COVID-19 vaccine starting in 2021, and possibly a billion doses a year.
Moderna in June 2020 entered into a deal with Catalent to produce the first 100 million doses of vaccine for the United States at its Indiana plant. It is planned that the supply of drugs will begin in the third quarter of 2020.
Moderna has announced that Amazon Web Services (AWS) has been chosen by it as its preferred cloud computing provider . As part of the partnership announced on Wednesday, the AWS cloud platform will be used as standard by Moderna for data analysis and machine learning.
The Federal Agency for Advanced Biomedicine Research and Development supported the company by allocating an additional $472 million to Moderna to fund the third phase of the trials.
 | Three candidate vaccines have now reached the third, final stage of clinical trials. We are investing in the development and production of vaccines, - said US President Donald Trump on August 12, 2020. - The military is ready to ensure the rapid delivery of six candidate vaccines once [the vaccines] are fully approved by the Food and Drug Administration (FDA). We are moving very quickly towards approval.[6] |  |
Notes
- ↑ Study finds third dose of BNT162b2 or mRNA-1273 is moderately effective against post-vaccination COVID-19 infection
- ↑ [Pfizer and Moderna raised the cost of their vaccines for the EU
- ↑ Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2
- ↑ 55 People Have Died in US After Receiving COVID-19 Vaccines: Reporting System
- ↑ Moderna Ditches 400,000 Vaccine Doses But Still Set to Meet Goal
- ↑ US government strikes $1.525 billion deal with Moderna for 100 million doses of its Covid-19 vaccine
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |